FULL TEST
TEST BANK FOR PHARMACOTHERAPEUTICS FOR
ADVANCED PRACTICE A PRACTICAL APPROACH 5TH
EDITION BY VIRGINIA POOLE ARCANGELO; ANDREW
PETERSON; VERONICA WILBUR; JENNIFER A. REINHOLD
PRINTED PDF I ORIGINAL DIRECTLY FROM THE PUBLISHER I 1OO%
VERIFIED ANSWERS ] DOWNLOAD IMMEDIATELY AFTER THE ORDER
['LIZ)LI12%5IL!
[LI.GIL
Complete Test bank, All Chapters are included.
For more Test banks, ATI, HES! exams, and more contact us.
, Table of content
Chapter I Issues for the Practitioner in Drug Therapy
Chapter 2 Pharmacokinetic Basis of Therapeutics and Pharmacodynamic Principles
Chapter 3 Impact of Drug Interactions and Adverse Events on Therapeutics
Chapter 4 Principles of Pharmacotherapy in Pediatrics, Pregnancy, and Lactation
Chapter 5 Pharmacotherapy Principles in Older Adults
Chapter 6 Principles of Antimicrobial Therapy
Chapter 7 Pharmacogenomies
Chapter 8 The Economics of Pharmacotherapeutics
Chapter 9 Pharmacotherapy of Pain Management
Chapter I0 Pain Management in Opioid Use Disorder (OUD) Patients
Chapter 11 Cannabis and Pain Management
Chapter 12 Contact Dermatitis
Chapter 13 Fungal, Viral, and Bacterial Infections of the Skin
Chapter 14 Psoriasis
Chapter I5 Acne Vulgaris and Rosacea
Chapter 16 Ophthalmic Disorders
Chapter I7 Otitis Media and Otitis Externa
Chapter I8 Hypertension
Chapter I9 Hyperlipidemia
Chapter 20 Chronic Stable Angina and Myocardial Infarction
Chapter 2I Heart Failure
Chapter 22 Arrhythmias
Chapter 23 Respiratory Infections
Chapter 24 Asthma and Chronic Obstructive Pulmonary Disease
Chapter 25 Gastric, Functional, and Inflammatory Bowel Disorders
Chapter 26 Gastroesophageal Reflux Disease and Peptic Ulcer Disease
Chapter 27 Liver Diseases
Chapter 28 Urinary Tract Infection
Chapter 29 Prostatic Disorders and Erectile Dysfunction
Chapter 30 Overactive Bladder
Chapter 3I Sexually Transmitted Infections
Chapter 32 Osteoarthritis and Gout
Chapter 33 Osteoporosis
Chapter 34 Rheumatoid Arthritis
Chapter 35 Headaches
Chapter 36 Seizure Disorders
Chapter 37 Alzheimer's Disease
Chapter 38 Parkinson's Disease
Chapter 39 Major Depressive Disorder and Bipolar Disorders
Chapter 40 Anxiety Disorders
Chapter 41 Sleep Disorders
Chapter 42 Attention Deficit Hyperactivity Disorder
Chapter 43 Substance Use Disorders
Chapter 44 Diabetes Mellitus
Chapter 45 Thyroid and Parathyroid Disorders
,Chapter 46 Allergies and Allergic Reactions
Chapter 47 Human Immunodeficiency Virus
Chapter 48 Organ Transplantation
Chapter 49 Thromboembolic Disorders
Chapter 50 Anemias
Chapter 5l Immunizations
Chapter 52 Smoking Cessation
Chapter 53 Weight Loss
Chapter 54 Contraception
Chapter 55 Menopause
Chapter 56 Vaginitis
, lOMoAR cPSD| 21007614
lOMoAR cPSD| 21007614
Chapter 1 Issues for the Practitioner in Drug Therapy
MULTIPLE CHOICE
1. Nurse practitioner prescriptive authority is regulated by:
A. The National Council of State Boards of Nursing
B. The U.S. Drug Enforcement Administration
C. The State Board of Nursing for each state
D. The State Board of Pharmacy
ANS: C PTS: 1
2. Physician Assistant (PA) prescriptive authority is regulated by:
A. The National Council of State Boards of Nursing
B. The U.S. Drug Enforcement Administration
C. The State Board of Nursing
D. The State Board of Medical Examiners
ANS: D PTS: 1
3. Clinical judgment in prescribing includes:
A. Factoring in the cost to the patient of the medication prescribed
B. Always prescribing the newest medication available for the disease process
C. Handing out drug samples to poor patients
D. Prescribing all generic medications to cut costs
ANS: A PTS: 1
4. Criteria for choosing an effective drug for a disorder include:
A. Asking the patient what drug they think would work best for them
B. Consulting nationally recognized guidelines for disease management
C. Prescribing medications that are available as samples before writing a prescription
D. Following U.S. Drug Enforcement Administration (DEA) guidelines for
prescribing
ANS: B PTS: 1
5. Nurse practitioner practice may thrive under health-care reform due to:
A. The demonstrated ability of nurse practitioners to control costs and improve patient
outcomes
B. The fact that nurse practitioners will be able to practice independently
C. The fact that nurse practitioners will have full reimbursement under health-care
reform
D. The ability to shift accountability for Medicaid to the state level
ANS: A PTS: 1
, lOMoAR cPSD| 21007614
Chapter 2.Pharmacokinetic Basis of Therapeutics and Pharmacodynamic
MULTIPLE CHOICE
1. A patient's nutritional intake and lab work reflects hypoalbuminemia. This is critical to
prescribing because:
A. Distribution of drugs to target tissue may be affected
B. The solubility of the drug will not match the site of absorption
C. There will be less free drug available to generate an effect
D. Drugs bound to albumin are readily excreted by the kidney
ANS: A PTS: 1
2. Drugs that have a significant first-pass effect:
A. Must be given by the enteral (oral) route only
B. Bypass the hepatic circulation
C. Are rapidly metabolized by the liver and may have little if any desired action
D. Are converted by the liver to more active and fat-soluble forms
ANS: C PTS: 1
3. The route of excretion of a volatile drug will likely be:
A. The kidneys
B. The lungs
C. The bile and feces
D. The skin
ANS: B PTS: 1
4. Medroxyprogesterone (Depo Provera) is prescribed IM to create a storage reservoir of the
drug. Storage reservoirs:
A. Assure that the drug will reach its intended target tissue
B. Are the reason for giving loading doses
C. Increase the length of time a drug is available and active
D. Are most common in collagen tissues
ANS: C PTS: 1
5. The NP chooses to give cephalexin every 8 hours based on knowledge of the drug's:
A. Propensity to go to the target receptor
B. Biological half-life
C. Pharmacodynamics
D. Safety and side effects
ANS: B PTS: 1
6. Azithromycin dosing requires the first day's dose be twice those of the other 4 days of the
prescription. This is considered a loading dose. A loading dose:
A. Rapidly achieves drug levels in the therapeutic range
B. Requires four to five half-lives to attain
C. Is influenced by renal function
, lOMoAR cPSD| 21007614
D. Is directly related to the drug circulating to the target tissues
ANS: A PTS: 1
7. The zpoint zin ztime zon zthe zdrug zconcentration zcurve zthat zindicates zthe zfirst zsign zof za
ztherapeutic zeffect zis zthe:
A. Minimum zadverse zeffect zlevel
B. Peak zof zaction
C. Onset zof zaction
D. Therapeutic zrange
ANS: z C PTS: z 1
8. Phenytoin zrequires za ztrough zlevel zbe zdrawn. zPeak zand ztrough zlevels zare zdone:
A. When zthe zdrug zhas za zwide ztherapeutic zrange
B. When zthe zdrug zwill zbe zadministered zfor za zshort ztime zonly
C. When zthere zis za zhigh zcorrelation zbetween zthe zdose zand zsaturation zof zreceptor zsites
D. To zdetermine zif za zdrug zis zin zthe ztherapeutic zrange
ANS: z D PTS: z 1
9. A zlaboratory zresult zindicates zthe zpeak zlevel zfor za zdrug zis zabove zthe zminimum
ztoxic zconcentration. zThis zmeans zthat zthe:
A. Concentration zwill zproduce ztherapeutic zeffects
B. Concentration zwill zproduce zan zadverse zresponse
C. Time zbetween zdoses zmust zbe zshortened
D. Duration zof zaction zof zthe zdrug zis ztoo zlong
ANS: z B PTS: z 1
10. Drugs zthat zare zreceptor zagonists zmay zdemonstrate zwhat zproperty?
A. Irreversible zbinding zto zthe zdrug zreceptor zsite
B. Up-regulation zwith zchronic zuse
C. Desensitization zor zdown-regulation zwith zcontinuous zuse
D. Inverse zrelationship zbetween zdrug zconcentration zand zdrug zaction
ANS: z C PTS: z 1
11. Drugs zthat zare zreceptor zantagonists, zsuch zas zbeta zblockers, zmay zcause:
A. Down-regulation zof zthe zdrug zreceptor
B. An zexaggerated zresponse zif zabruptly zdiscontinued
C. Partial zblockade zof zthe zeffects zof zagonist zdrugs
D. An zexaggerated zresponse zto zcompetitive zdrug zagonists
ANS: z B PTS: z 1
12. Factors zthat zaffect zgastric zdrug zabsorption zinclude:
A. Liver zenzyme zactivity
B. Protein-binding zproperties zof zthe zdrug zmolecule
C. Lipid zsolubility zof zthe zdrug
D. Ability zto zchew zand zswallow
ANS: z C PTS: z 1
TEST BANK FOR PHARMACOTHERAPEUTICS FOR
ADVANCED PRACTICE A PRACTICAL APPROACH 5TH
EDITION BY VIRGINIA POOLE ARCANGELO; ANDREW
PETERSON; VERONICA WILBUR; JENNIFER A. REINHOLD
PRINTED PDF I ORIGINAL DIRECTLY FROM THE PUBLISHER I 1OO%
VERIFIED ANSWERS ] DOWNLOAD IMMEDIATELY AFTER THE ORDER
['LIZ)LI12%5IL!
[LI.GIL
Complete Test bank, All Chapters are included.
For more Test banks, ATI, HES! exams, and more contact us.
, Table of content
Chapter I Issues for the Practitioner in Drug Therapy
Chapter 2 Pharmacokinetic Basis of Therapeutics and Pharmacodynamic Principles
Chapter 3 Impact of Drug Interactions and Adverse Events on Therapeutics
Chapter 4 Principles of Pharmacotherapy in Pediatrics, Pregnancy, and Lactation
Chapter 5 Pharmacotherapy Principles in Older Adults
Chapter 6 Principles of Antimicrobial Therapy
Chapter 7 Pharmacogenomies
Chapter 8 The Economics of Pharmacotherapeutics
Chapter 9 Pharmacotherapy of Pain Management
Chapter I0 Pain Management in Opioid Use Disorder (OUD) Patients
Chapter 11 Cannabis and Pain Management
Chapter 12 Contact Dermatitis
Chapter 13 Fungal, Viral, and Bacterial Infections of the Skin
Chapter 14 Psoriasis
Chapter I5 Acne Vulgaris and Rosacea
Chapter 16 Ophthalmic Disorders
Chapter I7 Otitis Media and Otitis Externa
Chapter I8 Hypertension
Chapter I9 Hyperlipidemia
Chapter 20 Chronic Stable Angina and Myocardial Infarction
Chapter 2I Heart Failure
Chapter 22 Arrhythmias
Chapter 23 Respiratory Infections
Chapter 24 Asthma and Chronic Obstructive Pulmonary Disease
Chapter 25 Gastric, Functional, and Inflammatory Bowel Disorders
Chapter 26 Gastroesophageal Reflux Disease and Peptic Ulcer Disease
Chapter 27 Liver Diseases
Chapter 28 Urinary Tract Infection
Chapter 29 Prostatic Disorders and Erectile Dysfunction
Chapter 30 Overactive Bladder
Chapter 3I Sexually Transmitted Infections
Chapter 32 Osteoarthritis and Gout
Chapter 33 Osteoporosis
Chapter 34 Rheumatoid Arthritis
Chapter 35 Headaches
Chapter 36 Seizure Disorders
Chapter 37 Alzheimer's Disease
Chapter 38 Parkinson's Disease
Chapter 39 Major Depressive Disorder and Bipolar Disorders
Chapter 40 Anxiety Disorders
Chapter 41 Sleep Disorders
Chapter 42 Attention Deficit Hyperactivity Disorder
Chapter 43 Substance Use Disorders
Chapter 44 Diabetes Mellitus
Chapter 45 Thyroid and Parathyroid Disorders
,Chapter 46 Allergies and Allergic Reactions
Chapter 47 Human Immunodeficiency Virus
Chapter 48 Organ Transplantation
Chapter 49 Thromboembolic Disorders
Chapter 50 Anemias
Chapter 5l Immunizations
Chapter 52 Smoking Cessation
Chapter 53 Weight Loss
Chapter 54 Contraception
Chapter 55 Menopause
Chapter 56 Vaginitis
, lOMoAR cPSD| 21007614
lOMoAR cPSD| 21007614
Chapter 1 Issues for the Practitioner in Drug Therapy
MULTIPLE CHOICE
1. Nurse practitioner prescriptive authority is regulated by:
A. The National Council of State Boards of Nursing
B. The U.S. Drug Enforcement Administration
C. The State Board of Nursing for each state
D. The State Board of Pharmacy
ANS: C PTS: 1
2. Physician Assistant (PA) prescriptive authority is regulated by:
A. The National Council of State Boards of Nursing
B. The U.S. Drug Enforcement Administration
C. The State Board of Nursing
D. The State Board of Medical Examiners
ANS: D PTS: 1
3. Clinical judgment in prescribing includes:
A. Factoring in the cost to the patient of the medication prescribed
B. Always prescribing the newest medication available for the disease process
C. Handing out drug samples to poor patients
D. Prescribing all generic medications to cut costs
ANS: A PTS: 1
4. Criteria for choosing an effective drug for a disorder include:
A. Asking the patient what drug they think would work best for them
B. Consulting nationally recognized guidelines for disease management
C. Prescribing medications that are available as samples before writing a prescription
D. Following U.S. Drug Enforcement Administration (DEA) guidelines for
prescribing
ANS: B PTS: 1
5. Nurse practitioner practice may thrive under health-care reform due to:
A. The demonstrated ability of nurse practitioners to control costs and improve patient
outcomes
B. The fact that nurse practitioners will be able to practice independently
C. The fact that nurse practitioners will have full reimbursement under health-care
reform
D. The ability to shift accountability for Medicaid to the state level
ANS: A PTS: 1
, lOMoAR cPSD| 21007614
Chapter 2.Pharmacokinetic Basis of Therapeutics and Pharmacodynamic
MULTIPLE CHOICE
1. A patient's nutritional intake and lab work reflects hypoalbuminemia. This is critical to
prescribing because:
A. Distribution of drugs to target tissue may be affected
B. The solubility of the drug will not match the site of absorption
C. There will be less free drug available to generate an effect
D. Drugs bound to albumin are readily excreted by the kidney
ANS: A PTS: 1
2. Drugs that have a significant first-pass effect:
A. Must be given by the enteral (oral) route only
B. Bypass the hepatic circulation
C. Are rapidly metabolized by the liver and may have little if any desired action
D. Are converted by the liver to more active and fat-soluble forms
ANS: C PTS: 1
3. The route of excretion of a volatile drug will likely be:
A. The kidneys
B. The lungs
C. The bile and feces
D. The skin
ANS: B PTS: 1
4. Medroxyprogesterone (Depo Provera) is prescribed IM to create a storage reservoir of the
drug. Storage reservoirs:
A. Assure that the drug will reach its intended target tissue
B. Are the reason for giving loading doses
C. Increase the length of time a drug is available and active
D. Are most common in collagen tissues
ANS: C PTS: 1
5. The NP chooses to give cephalexin every 8 hours based on knowledge of the drug's:
A. Propensity to go to the target receptor
B. Biological half-life
C. Pharmacodynamics
D. Safety and side effects
ANS: B PTS: 1
6. Azithromycin dosing requires the first day's dose be twice those of the other 4 days of the
prescription. This is considered a loading dose. A loading dose:
A. Rapidly achieves drug levels in the therapeutic range
B. Requires four to five half-lives to attain
C. Is influenced by renal function
, lOMoAR cPSD| 21007614
D. Is directly related to the drug circulating to the target tissues
ANS: A PTS: 1
7. The zpoint zin ztime zon zthe zdrug zconcentration zcurve zthat zindicates zthe zfirst zsign zof za
ztherapeutic zeffect zis zthe:
A. Minimum zadverse zeffect zlevel
B. Peak zof zaction
C. Onset zof zaction
D. Therapeutic zrange
ANS: z C PTS: z 1
8. Phenytoin zrequires za ztrough zlevel zbe zdrawn. zPeak zand ztrough zlevels zare zdone:
A. When zthe zdrug zhas za zwide ztherapeutic zrange
B. When zthe zdrug zwill zbe zadministered zfor za zshort ztime zonly
C. When zthere zis za zhigh zcorrelation zbetween zthe zdose zand zsaturation zof zreceptor zsites
D. To zdetermine zif za zdrug zis zin zthe ztherapeutic zrange
ANS: z D PTS: z 1
9. A zlaboratory zresult zindicates zthe zpeak zlevel zfor za zdrug zis zabove zthe zminimum
ztoxic zconcentration. zThis zmeans zthat zthe:
A. Concentration zwill zproduce ztherapeutic zeffects
B. Concentration zwill zproduce zan zadverse zresponse
C. Time zbetween zdoses zmust zbe zshortened
D. Duration zof zaction zof zthe zdrug zis ztoo zlong
ANS: z B PTS: z 1
10. Drugs zthat zare zreceptor zagonists zmay zdemonstrate zwhat zproperty?
A. Irreversible zbinding zto zthe zdrug zreceptor zsite
B. Up-regulation zwith zchronic zuse
C. Desensitization zor zdown-regulation zwith zcontinuous zuse
D. Inverse zrelationship zbetween zdrug zconcentration zand zdrug zaction
ANS: z C PTS: z 1
11. Drugs zthat zare zreceptor zantagonists, zsuch zas zbeta zblockers, zmay zcause:
A. Down-regulation zof zthe zdrug zreceptor
B. An zexaggerated zresponse zif zabruptly zdiscontinued
C. Partial zblockade zof zthe zeffects zof zagonist zdrugs
D. An zexaggerated zresponse zto zcompetitive zdrug zagonists
ANS: z B PTS: z 1
12. Factors zthat zaffect zgastric zdrug zabsorption zinclude:
A. Liver zenzyme zactivity
B. Protein-binding zproperties zof zthe zdrug zmolecule
C. Lipid zsolubility zof zthe zdrug
D. Ability zto zchew zand zswallow
ANS: z C PTS: z 1
